The Integrin Binding Peptide, ATN-161, As a Novel Therapy for SARS-CoV-2 Infection

Overview

Journal JACC Basic Transl Sci

Date 2020 Oct 26

PMID 33102950

Citations 58

Authors

Brandon J Beddingfield

Naoki Iwanaga

Prem P Chapagain

Wenshu Zheng

Chad J Roy

Tony Y Hu

Jay K Kolls

Gregory J Bix

Affiliations

Soon will be listed here.

Abstract

Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin-based mechanism and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/- ACE2) and the interaction between α5β1 integrin and ACE2 using a novel molecule (ATN-161) represents a promising approach to treat coronavirus disease-19.

Citing Articles

The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management.

Becker R, Tantry U, Khan M, Gurbel P J Thromb Thrombolysis. 2024; 58(1):15-49.

PMID: 39179952 PMC: 11762605. DOI: 10.1007/s11239-024-03028-4.

Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.

Tang X, Liu Y, Wang J, Long T, Yee Mok B, Huang Y J Biol Chem. 2024; 300(6):107390.

PMID: 38777146 PMC: 11237930. DOI: 10.1016/j.jbc.2024.107390.

SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors.

Behboudi E, Nooreddin Faraji S, Daryabor G, Hashemi S, Asadi M, Edalat F Heliyon. 2024; 10(4):e26577.

PMID: 38420467 PMC: 10901034. DOI: 10.1016/j.heliyon.2024.e26577.

Development of SARS-CoV-2 entry antivirals.

Dong M, Galvan Achi J, Du R, Rong L, Cui Q Cell Insight. 2024; 3(1):100144.

PMID: 38323318 PMC: 10844678. DOI: 10.1016/j.cellin.2023.100144.

Integrin αβ contributes to cell fusion and inflammation mediated by SARS-CoV-2 spike via RGD-independent interaction.

Zhang H, Wang Z, Nguyen H, Watson A, Lao Q, Li A Proc Natl Acad Sci U S A. 2023; 120(50):e2311913120.

PMID: 38060559 PMC: 10723138. DOI: 10.1073/pnas.2311913120.

References

Napione L, Cascone I, Mitola S, Serini G, Bussolino F . Integrins: a flexible platform for endothelial vascular tyrosine kinase receptors. Autoimmun Rev. 2007; 7(1):18-22. DOI: 10.1016/j.autrev.2007.03.007. View

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

Donate F, Parry G, Shaked Y, Hensley H, Guan X, Beck I . Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res. 2008; 14(7):2137-44. DOI: 10.1158/1078-0432.CCR-07-4530. View

Wang L, Shi Z, Zhang S, Field H, Daszak P, Eaton B . Review of bats and SARS. Emerg Infect Dis. 2007; 12(12):1834-40. PMC: 3291347. DOI: 10.3201/eid1212.060401. View

Lv X, Li Z, Guan J, Zhang J, Xu B, He W . ATN-161 reduces virus proliferation in PHEV-infected mice by inhibiting the integrin α5β1-FAK signaling pathway. Vet Microbiol. 2019; 233:147-153. DOI: 10.1016/j.vetmic.2019.04.029. View

Cianfrocca M, Kimmel K, Gallo J, Cardoso T, Brown M, Hudes G . Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer. 2006; 94(11):1621-6. PMC: 2361324. DOI: 10.1038/sj.bjc.6603171. View

Binder R, Alarja N, Robie E, Kochek K, Xiu L, Rocha-Melogno L . Environmental and Aerosolized Severe Acute Respiratory Syndrome Coronavirus 2 Among Hospitalized Coronavirus Disease 2019 Patients. J Infect Dis. 2020; 222(11):1798-1806. PMC: 7499634. DOI: 10.1093/infdis/jiaa575. View

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

Luan J, Lu Y, Gao S, Zhang L . A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2. J Infect. 2020; 81(2):318-356. PMC: 7151354. DOI: 10.1016/j.jinf.2020.03.046. View

10.

Caly L, Druce J, Catton M, Jans D, Wagstaff K . The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787. PMC: 7129059. DOI: 10.1016/j.antiviral.2020.104787. View

11.

Cao L, Goreshnik I, Coventry B, Case J, Miller L, Kozodoy L . De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020; 370(6515):426-431. PMC: 7857403. DOI: 10.1126/science.abd9909. View

12.

Yan S, Sun H, Bu X, Wan G . New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection. Front Pharmacol. 2020; 11:912. PMC: 7303337. DOI: 10.3389/fphar.2020.00912. View

13.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

14.

Wang Y, Liu M, Gao J . Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc Natl Acad Sci U S A. 2020; 117(25):13967-13974. PMC: 7322019. DOI: 10.1073/pnas.2008209117. View

15.

Guo D, Zhu Q, Zhang H, Sun D . Proteomic analysis of membrane proteins of vero cells: exploration of potential proteins responsible for virus entry. DNA Cell Biol. 2013; 33(1):20-8. PMC: 3880917. DOI: 10.1089/dna.2013.2193. View

16.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

17.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

18.

Ishibashi Y, Relman D, Nishikawa A . Invasion of human respiratory epithelial cells by Bordetella pertussis: possible role for a filamentous hemagglutinin Arg-Gly-Asp sequence and alpha5beta1 integrin. Microb Pathog. 2001; 30(5):279-88. DOI: 10.1006/mpat.2001.0432. View

19.

Adair B, Alonso J, Van Agthoven J, Hayes V, Ahn H, Yu I . Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis. Nat Commun. 2020; 11(1):398. PMC: 6972956. DOI: 10.1038/s41467-019-13928-2. View

20.

Edwards D, Salmeron K, Lukins D, Trout A, Fraser J, Bix G . Integrin α5β1 inhibition by ATN-161 reduces neuroinflammation and is neuroprotective in ischemic stroke. J Cereb Blood Flow Metab. 2019; 40(8):1695-1708. PMC: 7370357. DOI: 10.1177/0271678X19880161. View